+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
P

Actively Recruiting

Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.

Age: 1Year - 35YearsAll GendersPhase 3
112 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.

Age: 55Years - 90YearsAll GendersPhase 2
39 locations
O

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral nuvisertib TP-3654 in patients with intermediate or high-risk primary or secondary myelofibrosis. This Phase 12, multicenter, open-label trial includes patients who have previously been treated with JAK inhibitors or are ineligible for such treatments. The study aims to understand nuvisertibs effects in different patient groups based on prior treatment history and current medication use. Participants are assigned to one of three groups nuvisertib alone for those intolerant or resistant to JAK inhibitors nuvisertib added to stable doses of ruxolitinib for patients with lost or suboptimal response or nuvisertib combined with momelotinib for those previously treated with a JAK inhibitor other than momelotinib. Treatments are given orally, with dosing adjusted through dose escalation phases. The study monitors patients from initial treatment through ongoing assessment periods. Throughout the trial, participants undergo evaluations including spleen volume measurement by MRI or CT, symptom scoring using the Myelofibrosis Symptom Assessment Form, and monitoring for adverse events. Researchers track dose-limiting toxicities and treatment-emergent adverse events, as well as pharmacokinetic parameters like drug concentration and half-life. The study also assesses changes in symptoms and spleen size over time. Participation may last several months, with regular visits for assessments and safety monitoring until the studys completion.

Age: 18Years +All GendersPhase 1Phase 2
91 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations

1-10 of 15

1